Calithera Biosciences (CALA)
(Real Time Quote from BATS)
$0.02 USD
0.00 (0.00%)
Updated May 13, 2024 01:31 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CALA 0.02 0.00(0.00%)
Will CALA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CALA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CALA
KalVista (KALV) Stock Continues to Decline: Here's Why
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug
CALA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
Other News for CALA
ALX Oncology appoints Dillon as Chief Business Officer
Astria Therapeutics appoints Agarwal to board of directors
Tracking Baker Brothers Portfolio - Q4 2023 Update